ALLR: Allarity Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Quantisnow AI summary
Settled $4.9M Novartis liability plus interest for $1.0M payment; also first revenue-generating CLIA lab services contract announced Oct 30.
Historical context for ALLR
Across the 20 sessions after earlier ALLR headlines, the stock closed higher 12 times and lower 8 times, with a median move of 5.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ALLR | SPY |
|---|---|---|---|
| Oct 30, 2026 | Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue | -2.2% | -1.8% |
| Sep 30, 2026 | Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development | +8.8% | -0.2% |
| Sep 28, 2026 | Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research | -6.0% | -0.7% |
| Sep 15, 2026 | Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development | -5.1% | -0.5% |
| Sep 11, 2026 | Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement | -2.4% | +0.9% |
| Aug 14, 2026 | Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign | +0.7% | -0.2% |
Quantisnow market dataNASDAQ
ALLR
Allarity Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for ALLR
Full ALLR profile on Quantisnow Follow ALLR and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time